Using therapeutic drug monitoring to treat KPC-producing klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam

Mohamad Yasmin; Jennifer Hanrahan; Steven Marshall; Thomas P. Lodise; Liang Chen; Federico Perez; Barry Kreiswirth; Robert A. Bonomo

doi:10.1093/ofid/ofaa349

Using therapeutic drug monitoring to treat KPC-producing klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam

Mohamad Yasmin
, Jennifer Hanrahan
, Steven Marshall
, Thomas P. Lodise
, Liang Chen
, Federico Perez
, Barry Kreiswirth
, Robert A. Bonomo

Pharmacy

University at Buffalo

Louis Stokes Cleveland VA Medical Center
University of Toledo
Albany College of Pharmacy
Case Western Reserve University
Hackensack Meridian Health
Hackensack Meridian School of Medicine

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)-3-producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC-Klebsiella pneumoniae central nervous system infections.

Original language	English
Journal	Open Forum Infectious Diseases
Volume	7
Issue number	9
DOIs	https://doi.org/10.1093/ofid/ofaa349
State	Published - Sep 1 2020

Keywords

Antimicrobial resistance
CNS infections
Ceftazidime/avibactam
KPC
Therapeutic drug monitoring

Access to Document

10.1093/ofid/ofaa349

Cite this

@article{0a502fb0620f41249ddfb810fdeac445,

title = "Using therapeutic drug monitoring to treat KPC-producing klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam",

abstract = "This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)-3-producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC-Klebsiella pneumoniae central nervous system infections.",

keywords = "Antimicrobial resistance, CNS infections, Ceftazidime/avibactam, KPC, Therapeutic drug monitoring",

author = "Mohamad Yasmin and Jennifer Hanrahan and Steven Marshall and Lodise, \{Thomas P.\} and Liang Chen and Federico Perez and Barry Kreiswirth and Bonomo, \{Robert A.\}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).",

year = "2020",

month = sep,

day = "1",

doi = "10.1093/ofid/ofaa349",

language = "English",

volume = "7",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Using therapeutic drug monitoring to treat KPC-producing klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam

AU - Yasmin, Mohamad

AU - Hanrahan, Jennifer

AU - Marshall, Steven

AU - Lodise, Thomas P.

AU - Chen, Liang

AU - Perez, Federico

AU - Kreiswirth, Barry

AU - Bonomo, Robert A.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)-3-producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC-Klebsiella pneumoniae central nervous system infections.

AB - This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)-3-producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC-Klebsiella pneumoniae central nervous system infections.

KW - Antimicrobial resistance

KW - CNS infections

KW - Ceftazidime/avibactam

KW - KPC

KW - Therapeutic drug monitoring

UR - https://www.scopus.com/pages/publications/85096702059

U2 - 10.1093/ofid/ofaa349

DO - 10.1093/ofid/ofaa349

M3 - Article

SN - 2328-8957

VL - 7

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 9

ER -

Using therapeutic drug monitoring to treat KPC-producing klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this